According to Zacks, “RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. “
RenovoRx stock opened at $1.89 on Friday. The company has a fifty day simple moving average of $3.09 and a 200-day simple moving average of $4.50. RenovoRx has a 12-month low of $1.89 and a 12-month high of $16.74.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in RenovoRx in the third quarter valued at $73,000. Virtu Financial LLC acquired a new position in shares of RenovoRx during the fourth quarter worth about $64,000. Two Sigma Securities LLC purchased a new stake in RenovoRx during the third quarter worth about $108,000. Schonfeld Strategic Advisors LLC purchased a new stake in RenovoRx during the third quarter worth about $125,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in RenovoRx during the third quarter worth about $247,000. Institutional investors own 1.60% of the company’s stock.
RenovoRx Company Profile (Get Rating)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.